SironRX Therapeutics, a Cleveland, OH-based biotechnology company developing novel regenerative therapies to accelerate dermal and bone healing, closed a $3.4m Series A funding.
The round was led by North Coast Angel Fund, with participation from Cleveland Clinic, JumpStart Inc., Fletcher Spaght Investments, Glengary LLC, Ohio Tech Angel Fund III, Early Stage Partners, X Gen Ltd. and other individuals.
The company intends to use the funds to build its team and execute on key clinical-stage milestones.
Led by co-founder, President and CEO Rahul Aras, Ph.D., SironRX develops novel therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic that promote wound repair and prevent scarring of dermal wounds. Its lead product, JVS100 is a clinically tested product that encodes Stromal cell-Derived Factor-1 (SDF-1). SDF-1 is produced by the body in response to tissue injury and activates natural repair processes to prevent cell death and recruit stem cells to the damaged organ. For its first clinical indication, the company will evaluate the safety and efficacy of JVS-100 in the treatment of post-surgical wounds.
Claiborne Rankin, Managing Member of North Coast Angel Fund, is also SironRX’ Board Chairman.